Evidence map›Paper›PMID 40590376›Full record

ArticleRNA biology2025

SARS-CoV-2 RNA-binding protein suppresses extracellular miRNA release.

Hyejin Mun, Chang Hoon Shin, Qingxuan Fei, Andrea Estefania Lopez Giraldo, Kyoung-Min Choi, Ji Won Lee, Kyungmin Kim, Kyung-Won Min, Leilei Shi, Mark T Bedford and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RNA biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. How does NMR support SARS-CoV-2 protein-ligand interaction studies?Analytical and bioanalytical chemistry · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Hyejin MunDepartment of Oncology Science, University of Oklahoma, Oklahoma City, OK, USA.
Chang Hoon ShinDepartment of Oncology Science, University of Oklahoma, Oklahoma City, OK, USA.
Qingxuan FeiDepartment of Chemistry, University of Colorado, Denver, CO, USA.
Andrea Estefania Lopez GiraldoDepartment of Chemistry, University of Colorado, Denver, CO, USA.
Kyoung-Min ChoiDepartment of Oncology Science, University of Oklahoma, Oklahoma City, OK, USA.
Ji Won LeeDepartment of Biology, College of Natural Sciences, Gangneung-Wonju National University, Gangneung-si, Republic of Korea.
Kyungmin KimDepartment of Biology, College of Natural Sciences, Gangneung-Wonju National University, Gangneung-si, Republic of Korea.
Kyung-Won MinDepartment of Biology, College of Natural Sciences, Gangneung-Wonju National University, Gangneung-si, Republic of Korea.
Leilei ShiDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark T BedfordDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dong-Chan KimR&D Center, NOSQUEST Inc, Seongnam, Republic of Korea.
Yoo Lim ChunDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
Seonghyun RyuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Dongin KimDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Jeong Ho ChangDepartment of Biology Education, Kyungpook National University, Daegu, Republic of Korea.
Ryan T WestropeDepartment of Oncology Science, University of Oklahoma, Oklahoma City, OK, USA.
Michelle ShayDepartment of Oncology Science, University of Oklahoma, Oklahoma City, OK, USA.
Edward NguyenDepartment of Oncology Science, University of Oklahoma, Oklahoma City, OK, USA.
Junho K HurHanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Republic of Korea.
Abigail AgyendaDepartment of Pharmacy Practice and Pharmaceutical Science, College of Pharmacy, University of Minnesota, Duluth, MN, USA.
Nam Chul KimDepartment of Pharmacy Practice and Pharmaceutical Science, College of Pharmacy, University of Minnesota, Duluth, MN, USA.
Sung-Ung KangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, USA.
Woonghee LeeDepartment of Chemistry, University of Colorado, Denver, CO, USA.
Je-Hyun YoonDepartment of Oncology Science, University of Oklahoma, Oklahoma City, OK, USA.

Funding

UNDERSTANDING NO SIGNALING RESULTING IN NEUROPROTECTION.P50DA000266 · NIDA · JOHNS HOPKINS UNIVERSITY · PI WORLEY, PAUL F · 1985 to 2017
$45.2M
Poly (ADP-Ribose) and AIF in Neuronal InjuryR01NS067525 · NINDS · JOHNS HOPKINS UNIVERSITY · PI VALINA L. DAWSON, Ted M. Dawson · 2010 to 2026
$6.0M
Parthanatos, AIF and PAAN-1 in Neuronal InjuryR37NS067525 · NINDS · JOHNS HOPKINS UNIVERSITY · PI DAWSON, TED M., DAWSON, VALINA L. · 2015 to 2021
$5.3M
Intestinal exosomes in alcohol-induces liver injuryR01AA027532 · NIAAA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI YOON, JE-HYUN · 2019 to 2023
$1.7M
NIAAA NIH HHS R01 AA027532NIDA NIH HHS P50 DA000266NINDS NIH HHS R01 NS067525NINDS NIH HHS R37 NS067525
6 · The paper itself

Abstract

SARS-CoV-2 is the betacoronavirus causing the COVID-19 pandemic. Although the SARS-CoV-2 genome and transcriptome were reported previously, the function of individual viral proteins is largely unknown. Utilizing biochemical and molecular biology methods, we identified that four SARS-CoV-2 RNA-binding proteins (RBPs) regulate the host RNA metabolism by direct interaction with mature miRNA let-7b revealed by Nuclear Magnetic Resonance spectroscopy (NMR). SARS-CoV-2 RBP Nsp9 primarily binds mature miRNA let-7b, a direct ligand of the Toll-like Receptor 7 (TLR7), one of the potential SARS-CoV-2 therapeutics. Nsp9 suppresses host gene expression possibly by promoting let-7b-mediated silencing of a cellular RNA polymerase, POLR2D. In addition, Nsp9 inhibits extracellular release of let-7b and subsequent antiviral activity via TLR7. These results demonstrate that SARS-CoV-2 hijacks the host RNA metabolism to suppress antiviral responses and to shut down cellular transcription. Our findings of how a natural ligand of TLR7, miRNA let-7b, is suppressed by SARS-CoV-2 RBPs will advance our understanding of COVID-19 and SARS-CoV-2 therapeutics.

Indexed as

COVID-19MicroRNAsRNA-Binding ProteinsSARS-CoV-2Viral Nonstructural ProteinsHEK293 CellsHost-Pathogen InteractionsHumansProtein BindingToll-Like Receptor 7MicroRNAsmirnlet7 microRNA, humanRNA-Binding ProteinsTLR7 protein, humanToll-Like Receptor 7Viral Nonstructural Proteinslet-7bmiRNANsp9POLR2DSARS-CoV-2

Identifiers

PMID40590376
PMCPMC12239786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.